PALI Palisade Bio, Inc.
$2.06▲ +2.49%
Healthcare
Other
After hours
$2.03▼ -1.22%
Sep 11, 7:30 PM ET
Volume 2.40M
Avg Volume (10D) 1.81M
Key Metrics & Fundamentals
Market Cap
$359.00M
P/E Ratio
3.2
Div Yield
–%
52W Range
0.55 - 2.86
% vs 50 MA
1.49%
% vs 200 MA
6.04%
RSI-14
50.6
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.30
Free Cash Flow
-$7.60M
Gross Rev
$500,000
Gross Profit
$500,000
EBITDA
-$10.57M
COGS
–
Operating Exp
$12.20M
Operating Income
-$11.70M
EBIT
-$11.70M
Pretax Income
-$10.57M
Net Income
-$10.57M
EPS (Diluted)
-0.05
Price & Volume History
Loading chart…
Recent News
Palisade Bio to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 3, 2026 1:00 PM
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
GlobeNewswire · Aug 10, 2026 8:20 PM
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Benzinga · Jul 27, 2026 11:30 AM
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
GlobeNewswire · Jul 10, 2026 1:00 PM
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
Stocktwits · Jun 29, 2026 5:49 PM
Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study
MT Newswires · Jun 29, 2026 1:03 PM
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
GlobeNewswire · Jun 29, 2026 12:30 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See PALI's money flow as a full page
Social Sentiment
Avg +0.20 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.